Tuesday, Jan 21, 1986
South San Francisco, Calif. -- January 21, 1986 --Genentech, Inc. today announced a 2 for 1 stock split, effective for shareholders of record as of February 1, 1986. Genentech stock is traded in the National Market System under NASDAQ symbol GENE.
Genentech is a leading biotechnology company focusing on the development manufacture and marketing of pharmaceuticals produced by recombinant DNA technology. Company-developed products being marketed include human insulin, licensed to Eli Lilly, and Protropin® growth hormone, which the company is manufacturing and selling in the United States. Other products in the approval process or in various stages of clinical testing include alpha interferon, licensed to Hoffman La Roche; ACTIVASE tissue plasminogen activator for dissolving blood clots in heart attack victims; gamma interferon, an anti-cancer and anti-infective agent; and tumor necrosis factor, a promising treatment for certain cancers.
Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #